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Abstract
Rationale: Methylarginines are endogenous nitric oxide synthase inhibitors that have been implicated in animal models of
lung disease but have not previously been examined for their association with spirometric measures of lung function in
humans.
Objectives: This study measured serum concentrations of asymmetric and symmetric dimethylarginine in a representative
sample of older community-dwelling adults and determined their association with spirometric lung function measures.
Methods: Data on clinical, lifestyle, and demographic characteristics, methylated arginines, and L-arginine (measured using
LC-MS/MS) were collected from a population-based sample of older Australian adults from the Hunter Community Study.
The five key lung function measures included as outcomes were Forced Expiratory Volume in 1 second, Forced Vital
Capacity, Forced Expiratory Volume in 1 second to Forced Vital Capacity ratio, Percent Predicted Forced Expiratory Volume
in 1 second, and Percent Predicted Forced Vital Capacity.
Measurements and Main Results: In adjusted analyses there were statistically significant independent associations
between a) higher asymmetric dimethylarginine, lower Forced Expiratory Volume in 1 second and lower Forced Vital
Capacity; and b) lower L-arginine/asymmetric dimethylarginine ratio, lower Forced Expiratory Volume in 1 second, lower
Percent Predicted Forced Expiratory Volume in 1 second and lower Percent Predicted Forced Vital Capacity. By contrast, no
significant associations were observed between symmetric dimethylarginine and lung function.
Conclusions: After adjusting for clinical, demographic, biochemical, and pharmacological confounders, higher serum
asymmetric dimethylarginine was independently associated with a reduction in key measures of lung function. Further
research is needed to determine if methylarginines predict the decline in lung function.
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Introduction
Lung health and obstructive lung disease (OLD) are considered
health priorities in Australia and worldwide due to the significant
burden of disease associated with a decline in lung function. Age-
related decline in lung function is associated with increased risk of
OLD [1] as well as cardiovascular [2] and all-cause mortality [3].
Age-related decline in lung function is not well understood,
however smoking and asthma are well established risk factors
[4,5]. Lung function may also decline in the absence of established
risk factors and a search for additional risk factors is clearly
warranted.
Nitric oxide (NO), a key endogenous mediator, is well known for
its effects on cardiovascular function but less well known for its role
in lung physiology and pathophysiology. In the lung, NO plays a
major role in airway and vascular smooth muscle relaxation,
ventilation perfusion matching, neurotransmission, mucociliary
clearance, airway mucus secretion, and host defence [6]. It is also
involved in the pathophysiology of lung diseases including
pulmonary hypertension, airway hyper-responsiveness (AHR),
asthma, chronic obstructive pulmonary disease (COPD), and
Cystic Fibrosis (CF) [6,7].
In alveolar endothelial cells, airway epithelial cells, and
endothelial cells of the bronchial and pulmonary circulation,
NO is synthesised from the amino acid L-arginine by the
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constitutive enzyme isoform endothelial nitric oxide synthase
(eNOS) [8]. In airway cholinergic nerves, airway epithelial cells,
and type 1 pneumocytes, NO is also synthesised by the constitutive
enzyme isoform neuronal nitric oxide synthase (nNOS) [9]. An
inducible nitric oxide synthase isoform (iNOS) is also expressed in
epithelial and inflammatory cells of the airway following exposure
to proinflammatory cytokines, producing large amounts of NO
relative to that produced by eNOS and nNOS [10]. Altered
expression of each NOS isoform has been documented in a
number of lung diseases [11].
Given the importance of NO in lung physiology and its role in
airway pathology, a disturbed synthesis and/or availability of NO
might contribute to the development of impaired lung function
and airway disease. The methylarginine asymmetric dimethylar-
ginine (ADMA) is an endogenous inhibitor of NOS [12] that
inhibits the activity of all three NO synthase isoforms, and has
been shown to reduce NO concentrations in numerous cell types
[12,13,14,15,16]. Elevated plasma ADMA concentrations have
been consistently demonstrated in individuals with traditional
vascular risk factors and those with existing cardiovascular disease
[17]. Symmetric dimethylarginine (SDMA) is a related molecule
that has been reported to competitively inhibit arginine uptake in
vitro [17], potentially implicating it in vascular disease and other
conditions dependent on adequate NO availability [18].
Endogenous methylarginines are important potentially modifi-
able molecules that may be associated with impaired or declining
lung function and airway disease. This view is supported by the
following observations.
1. ADMA and SDMA limit NO availability through NOS
inhibition and/or L-arginine availability and NO is required
for normal lung function [6].
2. NO is responsible for the maintenance of normal pulmonary
endothelial function and recent studies have shown that
pulmonary endothelial dysfunction is associated with asthma
and COPD [19], all conditions in which NO synthesis and/or
availability is impaired.
3. It has recently been demonstrated that the lung is not only a
major source of NO but is also a major source of the NOS
inhibitor ADMA [20]. Bulau et al. demonstrated in mice that
pulmonary expression of type I protein arginine methyltrans-
ferase 1 was correlated with enhanced protein arginine
methylation and pulmonary ADMA degradation was under-
taken by the isoform 1 of the enzyme dimethylarginine
dimethylaminohydrolase (DDAH1). Furthermore, bronchoal-
veolar lavage fluid and serum exhibited almost identical
ADMA/SDMA ratios. Together, these observations suggest
that methylarginine metabolism by the pulmonary system
significantly contributes to circulating ADMA and SDMA
concentrations.
4. In both chronic pulmonary hypertensive rats and patients with
idiopathic pulmonary arterial hypertension there is a marked
increase in serum and tissue ADMA and SDMA concentra-
tions [21].
5. In mice, ADMA affects physiology and collagen formation in
the airways through alteration in the L-arginine metabolizing
pathways [22]. Consistent with this finding, dysregulation in L-
arginine metabolism is associated with airflow abnormalities in
severe asthma patients [23].
6. Pharmacological inhibitors of NOS have been used to study
the role of specific NOS isoforms in asthma and have provided
support for iNOS-mediated NO production in the potentiation
of airway inflammation [24]. In contrast, overexpression of
eNOS attenuates airway inflammation in a murine model of
allergic asthma [25]. It has been demonstrated that in a mouse
model of allergic asthma, increased lung ADMA concentra-
tions and decreased DDAH expression are associated with
airway inflammation following allergen challenge [26]. These
findings provide support for the role of endogenous ADMA in
allergen-induced lung inflammation.
7. ADMA concentrations are also increased in human asthma
lung and sputum samples [27].
Hence an increase in endogenous ADMA and/or SDMA, may
contribute to the underlying pathology of decline in lung function
in humans through a direct influence on NOS isoforms and/or
depletion of L-arginine which is required for adequate synthesis of
NO. Given that no previous study has examined the association of
endogenous methylarginines with spirometric lung function, the
primary aim of this research is to measure serum concentrations of
the methylarginines ADMA and SDMA in a representative sample
of older community-dwelling adults and determine their associa-
tion with spirometric measures of lung function. We show that in a
sample of older community-dwelling adults, increased serum
ADMA is associated with reduced measures of lung function as
measured by spirometry.
Methods
Data for this study was obtained from the Hunter Community
Study (HCS), a cohort of community-dwelling men and women
aged 55 to 85 years of age in Newcastle, New South Wales (NSW),
Australia. Approval to conduct the research was granted by the
University of Newcastle Human Research Ethics Committees and
written informed consent was obtained from all study participants.
This study has been described in detail elsewhere [28]. In brief,
participants were randomly selected from the New South Wales
State Electoral roll and 9,784 individuals were contacted between
December 2004 and May 2007. Of these, a total of 3,253 actually
participated (response rate 44.5% after removing incorrect
addresses and non-contacts). Participants completed a series of
self-reported questionnaires, attended a clinic visit, and consented
to linkage of health records. For full details of this cohort and
sample characteristics see McEvoy M. et al., 2010 [28]. The
sample for this investigation (n= 500) was derived from the initial
cohort by simple random sampling. Of the 500 subjects randomly
selected there were complete exposure and outcome data for 483
subjects.
Main exposure variables: L-arginine and methylarginines
The primary explanatory variables were serum ADMA and
SDMA concentrations. Secondary variables were L-arginine, and
L-arginine/ADMA ratio. As L-arginine is the substrate for NOS-
dependent synthesis of NO we hypothesize that higher L-arginine,
and L-arginine/ADMA ratio will be associated with improved
lung function. Blood was collected in EDTA tubes and centrifuged
at 4uC and 3000 g for 10 min. to separate serum, which was
stored for three years at 280uC before analysis. L-Arginine and its
di-methylated forms (ADMA and SDMA) were measured in
serum by hydrophilic- interaction liquid chromatography and
isotope dilution tandem mass spectrometry [29]. The intra and
inter-assay CV’s for arginine, ADMA and SDMA were all less
than 15%.
Primary outcomes. Spirometry was used to measure Forced
Expiratory Volume in 1 sec. (FEV1) and Forced Vital Capacity
(FVC) and was performed using electronic spirometers (Micro
Medical SpiroUSB, Cardinal Health, Kent, UK) with Spida 5
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software (Carefusion Ltd, Kent, UK) and predicted values of Gore
[30]. The five key lung function measures included as outcomes in
this investigation were FEV1, FVC FEV1/FVC, %Predicted
FEV1, and %Predicted FVC. Spirometers were calibrated daily
using a 3-L syringe. All values obtained were corrected to body
temperature and ambient pressure, saturated with water vapour
(BTPS), with an assumed fixed room temperature and atmospher-
ic pressure. Lung function measures were measured in accordance
with the American Thoracic Society (ATC) guidelines [31].
Study factors
A number of factors were chosen a priori for testing association
with lung function. These factors were selected based on existing
knowledge derived from reviewing the literature and included the
participant’s age, gender, marital status, education level, house-
hold income, height, smoking status, alcohol intake, self-reported
medical & surgical history (clinician diagnosis), mean systolic blood
pressure, mean diastolic blood pressure, pulse pressure, number of
general practitioner visits, Short Form-36 physical function score
(Pf), Centre for Epidemiologic Studies Depression Scale depressive
symptom score (CESD depressive symptoms), self-reported med-
ication use, step count, Body Mass Index (BMI), Waist-to-Hip
Ratio (WHR), creatinine, urea, urate, Glomerular Filtration Rate
(GFR), fasting glucose, HDL cholesterol (HDL), LDL cholesterol
(LDL), triglycerides, white blood cell count (WBC), haemoglobin,
serum fibrinogen, serum homocysteine (measured using laser-
induced fluorescence capillary electrophoresis) and serum C-
reactive protein (CRP) (measured using latex-enhanced immuno-
turbidimetry).
Statistical Analysis
The statistical analysis was performed using STATA software
version 12.0 (Stata Corporation, College Station, TX, USA). The
analyses include twenty models that examine the association of the
L-arginine and methylarginine measures (ADMA, SDMA, L-
arginine, and L-arginine/ADMA ratio) with each of the five lung
function measures. Multiple linear regression was used to examine
the associations, initially with simple linear regression analysis for
each factor and then followed by multivariate analyses, to assess
the independent effects after controlling for other potential
confounders or covariates. The models were constructed by
backward elimination using the following procedures: 1) only
variables with p-value,0.20 in the univariate analysis were
entered into the models for backward elimination; 2) the screened
variables (potential confounders) were included in the model and
the non-significant variables (p.0.05) were manually eliminated
step by step and 3) any variables removed from the final regression
model due to collinearity were reported. The main predictor
variable (ADMA, SDMA, L-Arginine or L-Arginine/ADMA) was
retained in all the final models. The coefficients with 95%
confidence intervals were calculated in order to assess the adjusted
risk of independent variables, and those with p,0.05 were
retained in the final model.
Results
From the sample of 483 participants [median age (IQR) = 64
(60–70) years; Females = 54%], the prevalence of obstructive
ventilatory defect defined by the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) as a FEV1/FVC ratio below
70% was 6.6% (N=32). The means of each lung function
outcome (FEV1, FVC, FEV1/FVC, %Predicted FEV1, and
%Predicted FVC) were 2.48 litres (S.D= 0.69), 2.99 litres
(S.D= 0.83), 0.83 (S.D. = 0.08), 89.95% (S.D= 16.46), and
86.02% (S.D=14.91) respectively. Each predictor (ADMA,
SDMA, L-arginine, and L-arginine/ADMA ratio) was divided
into quartiles of serum values in mmol/L with quartile 1 (Q1) as
the lowest level (reference level) and quartile 4 (Q4) the highest
level. The median plasma concentrations of each primary
predictor within the lowest and highest quartile are described in
Table 1. Participant characteristics in the lowest and highest
quartile of each primary predictor are described in Table 2.
Simple linear regression analyses of quartiles of ADMA, SDMA,
L-arginine, and L-arginine/ADMA ratio with FEV1, FVC,
FEV1/FVC, %Predicted FEV1, and %Predicted FVC are
described in Table 3. In unadjusted analyses higher ADMA
was statistically significantly associated with a reduction in all lung
function measures. Furthermore, there was a general trend toward
a greater reduction with increasing concentrations of ADMA.
With the exception of FEV1/FVC, higher L-arginine/ADMA
ratio was statistically significantly associated with an increase in all
lung function measures. In unadjusted analyses, SDMA was only
statistically significantly associated with FEV1. There was no
association between L-arginine and any of the lung function
measures.
In further analyses, age, gender, marital status, education,
household income, height, asthma, angina, previous heart attack,
high cholesterol, atrial fibrillation, hypertension, CESD depressive
symptoms, alcohol, smoking years, number of general practice
visits, Pf, urea, urate, LDL, HDL, fibrinogen, homocysteine, GFR,
CRP, pulse pressure, and medications (consumption of cardiovas-
cular, anticholinergic, NSAID medicines) were all statistically
significantly associated with FEV1 in a simple linear regression
model. These same variables, with the exception of heart attack
and use of anticholinergic medicines, were also statistically
significantly associated with FVC. Furthermore, gender, marital
status, education, household income, height, asthma, heart attack,
atrial fibrillation, CABG, alcohol, number of general practice
visits, urea, urate, and medications (consumption of cardiovascular
and anticholinergic medicines) were statistically significantly
associated with FEV1/FVC in a simple linear regression model.
We also explored the association of other potential predictors
with %Predicted FEV1 and %Predicted FVC. Gender, marital
status, education, household income, asthma, heart attack, high
cholesterol, atrial fibrillation, hypertension, alcohol, smoking
years, number of general practice visits, pf, urea, urate, WBCC,
fasting glucose, fibrinogen, homocysteine, CRP, pulse pressure,
and medications (consumption of cardiovascular and anticholin-
ergic medicines) were all statistically significantly associated with
%Predicted FEV1in univariate analysis. These same variables,
Table 1. Median serum concentration of Asymmetric
dimethylarginine (ADMA), Symmetric dimethylarginine
(SDMA), L-arginine, and L-arginine/ADMA ratio in lowest
(Quartile 1) and highest (Quartile 4) quartile of each predictor
(N= 483).
Predictor Quartile 1 (95% CI)* Quartile 4 (95% CI)
ADMA (mmol/L) 0.45 (0.45–0.46) 0.64 (0.63–0.65)
SDMA (mmol/L) 0.54 (0.53–0.55) 0.96 (0.94–0.99)
L-arginine (mmol/L) 32.7 (31.4–34.0) 80.2 (78.2–82.1)
L-arginine/ADMA
ratio
61.3 (58.7–64.0) 148.3 (144.2–152.3)
*95% confidence interval.
doi:10.1371/journal.pone.0058390.t001
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with the exception of CABG and CESD depressive symptoms,
were also statistically significantly associated with %Predicted
FVC.
Multiple linear regression analyses of quartiles of ADMA,
SDMA, L-arginine, and L-arginine/ADMA ratio with FEV1 are
described in Table 4. In adjusted analysis ADMA (Q3), gender,
education, asthma, number of general practice visits, age, height,
smoking years, Pf, urate, and fibrinogen remained statistically
significant predictors of FEV1. In combination these variables
explained 66.12% of the total variation in FEV1. Quartile 3 of
ADMA concentration was associated with a reduction of FEV1 of
0.112 litres compared with Q1 while Q4 of ADMA concentration
was associated with a reduction of FEV1 of 0.098 litres compared
with Q1, but this did not reach statistical significance. In adjusted
analysis L-arginine/ADMA ratio (Q4), gender, education, house-
hold income, asthma, Pf, and fibrinogen remained statistically
significant predictors of FEV1. In combination these variables
explained 62.71% of the total variation in FEV1. Quartile 4 of the
L-arginine/ADMA ratio was associated with an increase of FEV1
of 0.130 litres compared with Q1. The analogous multivariate
regression with %predicted FEV1 is shown in Table S1; the
pattern of significant variables was similar as with FEV1 but was
less marked. There were no statistically significant associations
between SDMA and L-arginine with FEV1, however quartile 4 of
L-arginine was associated with an increase in %Predicted FEV1 of
approximately 3.7%.
Multiple linear regression analyses of quartiles of ADMA,
SDMA, L-arginine, and L-arginine/ADMA ratio with FVC are
described in Table 5. In adjusted analysis ADMA (Q3), gender,
education, age, height, smoking years, Pf, and fibrinogen remained
statistically significant predictors of FVC. In combination these
variables explained 66.40% of the total variation in FVC. Quartile
3 of ADMA concentration was associated with a reduction of FVC
of 0.137 litres compared with Q1. The analogous multivariate
regression with %predicted FVC is shown in Table S2; the pattern
of significant variables was similar as with FVC but was less
marked.
Multiple linear regression analyses of quartiles of ADMA,
SDMA, L-arginine, and L-arginine/ADMA ratio with FEV1/
FVC are described in Table 6. In adjusted analysis there was no
statistically significant association with ADMA, SDMA, L-
arginine, or L-arginine/ADMA ratio with FEV1/FVC. However,
household income, asthma, smoking years, and height remained
statistically significant predictors of FEV1/FVC in all four models.
Discussion
This population-based cross-sectional study of older Australian
men and women examined the association of plasma L-arginine
and the endogenous methylarginines, ADMA and SDMA with
spirometric measures of lung function. In unadjusted analyses,
ADMA and L-arginine/ADMA ratio were both statistically
significantly associated with FEV1, FVC, and FEV1/FVC. These
associations were attenuated but remained largely significant for
ADMA and L-arginine/ADMA ratio with FEV1 and FVC with
adjustment for a wide range of potential confounders. In none of
the analyses was SDMA associated with any measures of
spirometric lung function.
This research provides evidence to support the hypothesis that
higher serum concentrations of the endogenous methylarginine
ADMA are associated with lower measures of spirometric lung
function in older adults. To the best of our knowledge, this is the
first study to examine the association of serum L-arginine and the
endogenous methylarginines with lung function in humans. The
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only known study to examine the effect of ADMA on airway
hyperresponsiveness and lung function was performed in mice
who received an osmotically delivered infusion of ADMA [22]. In
this study ADMA infusion resulted in significantly enhanced lung
resistance (RL) and decreased dynamic compliance (Cdyn) in
response to methacholine. Furthermore, these physiologic changes
were associated with significantly increased lung collagen content
in the absence of inflammation. The results of this animal study
support the findings from the current investigation and provide
further evidence that higher concentrations of ADMA contribute
to abnormal airway physiology.
Despite extensive data implicating NO in the maintenance of
healthy airways and in the development of lung disease, there are
very few data describing the effects of pharmacological NOS
inhibitors on lung function in animals including humans. In one
study, administration by aerosol of the NOS inhibitors, N-omega-
nitro-L-arginine methyl ester (L-NAME) or NG-monomethyl-L-
arginine (L-NMMA), to spontaneously breathing anesthetized
guinea pigs resulted in a significant enhancement of lung resistance
(RL) after increasing intravenous doses of histamine [32]. In
another study L-NAME markedly augmented the response of
artificially ventilated guinea pigs to aerosolized ovalbumin
challenge, the potentiation of which could be prevented by NO
in the inhaled air [33]. L-NAME has also been shown to inhibit
the lipopolysaccharide induced airway hyporesponsiveness nor-
mally observed 9612 h following bacterial exposure [34].
Moreover, L-NMMA attenuated both the ovalbumin-induced
cellular influx and Evans blue leakage into the bronchoalveolar
lavage (BAL) fluid and potentiated the hyperresponsiveness to
methacholine in allergic Piebald-Virol-Glaxo rats [35]. More
recently in a study involving asthmatic subjects, administration of
nebulised L-NMMA resulted in a significant fall in peak exhaled
NO compared with saline control values, which persisted for
4 hours. However, there were no effects of L-NMMA inhalation
on heart rate, blood pressure, or FEV1 in either normal or
asthmatic patients [36]. Wells SM et al used a mouse lung
epithelial cell line to demonstrate that after LPS and cytokine
stimulation, elevated ADMA inhibits NOS and contributes to the
production of reactive oxygen and nitrogen species in vitro [22]
that is characteristic of many lung diseases. In a randomised,
double-blind, placebo-controlled, cross-over design study of 10
mildly asthmatic patients there was a statistically significant
difference in the mean of the provocative dose producing a 20%
fall in FEV1 to bradykinin between those receiving aerosol of L-
NMMA or saline (placebo) [37]. L-NMMA also caused a decrease
in the provocative concentration of methacholine producing a
20% fall in FEV1 from 0.93 mg/mL (range 0.12–2.55 mg/mL) to
0.38 mg/mL (range 0.06–0.92 mg/mL; p,0.01). The results
suggest that bronchoconstriction after bradykinin inhalation is
greatly inhibited by the formation of NO in airways of asthmatic
patients and that NO could have a bronchoprotective role in
asthma. As discussed previously, several animal studies have
demonstrated that NOS inhibitors have provided support for
iNOS-mediated NO production in the potentiation of airway
inflammation [24]. In contrast, overexpression of eNOS attenuates
airway inflammation in a murine model of allergic asthma [25]
providing support for the hypothesis that eNOS-derived NO has a
protective effect on airways while iNOS-induced NO augments
airway inflammation. In the respiratory tract, NO is produced by
a wide variety of cells, including epithelial cells, airway nerves,
inflammatory cells, and vascular endothelial cells. Further studies
will be necessary to identify the key cellular targets for NOS
inhibition by ADMA as well as the relative involvement of each of
the NOS isoforms.
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The absence of an inverse association of SDMA with
spirometric lung function measures in this study in multivariate
analyses is surprising given that SDMA inhibits the cellular uptake
of L-arginine, and could potentially exert its effects on lung
function by depletion of the L-arginine pool which is required for
adequate synthesis of NO. However, the absence of a significant
inverse association between SDMA and lung function in the
presence of a significant association with ADMA suggests that
impairment in lung function is likely to be mediated through
effects on NOS and not some other mechanism.
These findings are important given that other research that has
demonstrated higher concentrations of serum ADMA are associated
with OLD [27]. Reduced lung function is a risk factor for the
development of OLD, hence confirmation that ADMA is associated
with lung function impairment and/or decline in longitudinal studies
might pave the way for interventional studies during this stage as a
means of preventing decline. Given that ADMA concentrations can
be modulated by non-pharmacological and pharmacological inter-
ventions it is important to determine if methylarginines are a
potentially modifiable risk factor for impaired lung function andOLD.
This study has a number of strengths. The research was conducted
in a relatively large population-based sample of community-dwelling
older adults and hence the external validity of the findings is sound.
Secondly, serum L-arginine, ADMA, and SDMAwere all measured
using hydrophilic-interaction liquid chromatography and isotope
dilution tandem mass spectrometry, currently the gold standard for
methylarginine measurement. The coefficients of variation of
analytical runs were all within accepted limits and the hence the
assays had good reliability. Finally, lung function was measured
objectively with spirometry according to ATC guidelines [31].
Limitations of our study include its cross-sectional nature, which
does not allow the assessment of cause-effect relationship between
methylarginines and lung function. Hence, ADMA may simply be
a marker of spirometric lung function. Moreover, similarly to most
population studies on methylated arginines, the measurement of
ADMA and SDMA from blood does not necessarily reflect
intracellular concentrations of these compounds.
In summary, this study has shown that higher serum ADMA
concentrations are associated with reduced spirometric measures
of lung function while a higher L-arginine to ADMA ratio is
associated with increased FEV1, increased percent of predicted
FEV1, and increased percent of predicted FVC in an older
population. Further research is needed to confirm if higher serum
methylarginines are associated with the decline in lung function
and incident obstructive lung disease.
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Table S1 Adjusted b -coefficient and 95% confidence
intervals obtained from a multiple linear regression
Table 6. Adjusted b -coefficient and 95% confidence intervals obtained from a multiple linear regression analysis of Asymmetric
dimethylarginine, symmetric dimethylarginine, L-arginine, and L-arginine/asymmetric dimethylarginine ratio with for the ratio
FEV1/FVC.
Characteristic Adjusted Adjusted Adjusted Adjusted
b* 95% CI{ p` b 95% CI p b 95% CI p b 95% CI p
Predictors Asymmetric dimethylarginine Symmetric dimethylarginine L-Arginine L-arginine/ADMA ratio
Quartile 1 Ref Ref Ref Ref
Quartile 2 0.006 20.013, 0.024 0.550 20.002 20.019,
0.016
0.844 20.014 20.033,
0.005
0.152 20.018 20.040,
0.003
0.087
Quartile 3 0.005 20.014, 0.024 0.592 20.014 20.032,
0.003
0.109 20.015 20.035,
0.006
0.164 20.003 20.021,
0.015
0.773
Quartile 4 20.010 20.030, 0.009 0.301 20.003 20.023,
0.016
0.739 0.009 20.009,
0.027
0.320 0.010 20.008,
0.028
0.264
Household income
,A$40,000 Ref Ref Ref Ref
.=A$40,000 0.026 0.013, 0.039 ,0.001 0.026 0.013,
0.039
,0.001 0.027 0.014,
0.040
,0.001 0.027 0.014,
0.040
,0.001
Asthma
No Ref Ref Ref Ref
Yes 20.064 20.091, 20.036 ,0.001 20.067 20.094,
20.039
20.068 20.068 20.095,
20.040
,0.001 20.067 20.094,
20.040
,0.001
Smoking years 20.001 20.001, 0.000 0.005 20.001 20.001,
0.000
0.003 20.001 20.001,
0.000
0.003 20.001 20.001,
0.000
0.002
Height 20.001 20.002, 20.001 0.001 20.001 20.002,
20.001
0.001 20.001 20.002,
20.001
0.001 20.001 20.002,
20.001
,0.001
Adjusted R-squared
%
16.91 16.74 17.84 17.92
Independent variables adjusted for based on p-value,0.20 are: gender, marital status, education, household income, height, asthma, heart attack, atrial fibrillation,
coronary artery bypass graft, alcoholic drink days per month, number of general practice visits, urea, urate, cardiovascular medication use, anticholinergic medication
use.
*b -coefficient;
{95% confidence interval;
`p-value.
doi:10.1371/journal.pone.0058390.t006
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ric dimethylarginine ratio with percent predicted FEV1.
(DOCX)
Table S2 Adjusted b -coefficient and 95% confidence
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